A descriptive analysis of 54 pulmonary arterial hypertension-related clinical studies registered on international platforms in 2025 was recently published in Pulmonary Therapeutics. The review reveals an evolving and increasingly sophisticated research landscape. Nearly two thirds of the studies were interventional and one third observational, with most involving pharmacological interventions. Most trials involved pharmacological interventions and were conducted predominantly in high- and middle-income countries, with limited representation from low-income regions.
Key findings and trends include:
- Diversification of therapeutic targets — research is moving beyond classical vasodilator pathways, with growing focus on TGF-β/BMP signalling modulation, metabolic and cardiorenal pathways, and selective tyrosine kinase inhibition
- Beyond symptom control — many studies now aim to preserve right ventricular function and reduce long-term strain on the heart, using composite endpoints that combine clinical, physical, imaging, biomarker and laboratory assessments
- Methodological refinement — trials increasingly incorporate imaging-based assessments, biomarkers and composite endpoints to better capture disease progression and treatment response
- Patient-centred approaches — patient-reported outcome measures and disease literacy assessments are increasingly included alongside traditional medical tests
- Digital health — a subset of studies are using remote monitoring and home-based tools to track symptoms, physical activity and treatment adherence between clinic visits
- Funding and sponsorship — academic institutions and hospitals account for the majority of sponsors, with direct pharmaceutical industry sponsorship identified in only a minority of registrations
- Global equity — research remains concentrated in high- and middle-income countries, with very limited representation from low-income regions — a persistent and important gap to address
Overall, these developments reflect a maturing field and offer cautious optimism for more personalised and comprehensive care for people living with pulmonary arterial hypertension.
Read more at this link on Pulmonary Therapy
Citation
Nascimento IAO, Souza R, Fernandes CJCDS. 2025 Annual Review of Pulmonary Arterial Hypertension Clinical Research. Pulm Ther. 2026 Apr 8. doi: 10.1007/s41030-026-00359-w. Epub ahead of print. PMID: 41952025.